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Pulmonary tuberculosis (PTB), caused by Mycobacterium tuberculosis (Mtb), is a major
health problem worldwide, further aggravated by the convergence of type 2 diabetes
mellitus (DM) which constitutes an important risk factor for TB development. The worse
scenario of patients with PTB and DM may be partly related to a more unbalanced
defensive response. As such, newly diagnosed PTB patients with DM (TB+DM, n = 11)
or not (TB, n = 21), as well as DM (n = 18) patients and pair matched controls (Co, n
= 22), were investigated for the circulating immuno-endocrine-metabolic profile (ELISA),
along with studies in peripheral blood mononuclear cells (PBMC) analyzing transcript
expression (RT-qPCR) of mediators involved in glucocorticoid functionality. Given
the hyperglycemic/hypercortisolemic scenario of TB+DM patients, PBMC were also
exposed to stress-related cortisol concentrations (0.1 and 1µM) and supraphysiologic
glucose doses (10, 20, and 40mM) and assessed for the specific response against
Mtb stimulation (lymphoproliferation, -thymidine incorporation-, and cytokine production
-bead-cytometry). All TB patients displayed increased plasma amounts of cortisol,
growth hormone -hGH-, and proinflammatory mediators. In turn, TB+DM showed even
higher levels of interferon gamma -IFN-γ- and hGH (vs. TB), or IL-6, C reactive protein,
cortisol and hGH (vs. DM). Both DM groups had equally augmented values of IL-10. All
TB patients showed decreased dehydroepiandrosterone- sulfate concentrations, even
more in TB+DM cases. Leptin was also decreased in both TB cases, particularly in the TB
group, revealing a lower body mass index, as well. Unlike PBMC from TB cases showing
a decreased relationship between the glucocorticoids receptor (GR) isoforms (GRα/GRβ;
functional isoform/negative isoform), cells from TB+DM patients had no changes in this
regard, along with an increased expression of 11-beta hydroxysteroid dehydrogenase
type-1, the enzyme facilitating intracellular cortisone to cortisol conversion. TB+DM
patients also showed an increased Mtb antigen-driven lymphoproliferation. Compared
to TB, DM and HCo counterparts, PBMC from TB+DM patients had a biased Th1
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response to Mtb stimulation (increased IL-2 and IFN-γ production), even when
exposed to inhibitory cortisol doses. TB+DM patients show a more unbalanced
immuno-endocrine relationship, respect the non-diabetic counterparts, with a relative
deficiency of cortisol immunomodulatory influences, despite their more favorable
microenvironment for cortisol-mediated immune effects.
Keywords: pulmonary tuberculosis, diabetes mellitus type 2, immune-endocrine alterations, cortisol, glucose
INTRODUCTION
Pulmonary tuberculosis (PTB) is a major health problem around
the world and the leading cause of death due to a pathogen,
Mycobacterium tuberculosis (Mtb). In 2017, WHO reported 10
million new PTB cases, 15% of them attributed to the TB-
type 2 diabetes mellitus (TB-DM) comorbidity (1). Tuberculosis
clinical manifestations result from a complex interaction between
its etiologic agent, and the defensive reactions developed to
control infection, but its proper basis is not fully understood
(2). Endocrine disturbances are likely to contribute to disease
pathology, since DM increases more than three times the
possibility of developing active PTB, which otherwise develop in
5–10% of Mtb-infected individuals. In addition to this increased
risk, PTB patients with concomitant diabetes are at higher rates
of treatment failure and death (3–6). Within this setting, we
have recently demonstrated that patients with TB+DM showed a
more pronounced adverse immune-endocrine profile than those
with PTB alone (TB group) (7), for instance higher circulating
amounts of cortisol.
Besides its metabolic functions, cortisol acts as an
extrinsic regulator of the immune response (IR) inhibiting, at
supraphysiologic concentrations, the proinflammatory response
as well as the specific cellular IR againstMtb (8). Glucocorticoids
(GC) are known to reduce the production of various cytokines
such as tumor necrosis factor alpha (TNF-α), interleukins, as well
as inflammatory enzymes, e.g., cyclooxygenase 2 and inducible
nitric oxide synthase (9). Most immunological effects of GC
are mediated by GRα isoform, whereas GRβ lacks the ability to
bind GC and seems to function as an inhibitor of GRα-mediated
transcriptional activation through the formation of GRα/GRβ
heterodimers (10). It follows that this ratio may be related with
GC functionality.
While increased susceptibility to PTB in DM patients may be
linked to alterations on macrophage and lymphocyte functions
(11, 12), partly related to a higher cortisol production, other
factors like hyperglycemia and insulin resistance are also likely
to account for such detrimental influence (3). Several studies
indicate that diabetes and hyperglycemia coexist with impaired
innate immune responses like phagocytosis, cytokine secretion
and macrophage activation (13–17). Nevertheless, in a more
recent in vitro study, Lachmandas et al. provided evidence
that hyperglycemia failed to affect the functional capacity of
macrophages against Mtb while being able to increase cytokine
production upon mycobacterial and LPS stimulation (18).
Given this background, in the present study we sought
to analyze various systemic mediators involved in the
immuno-endocrine-metabolic interrelation: IFN-γ, IL-6,
IL-10, IL-4, IL-1β, cortisol, dehydroepiandrosterone-sulfate
(DHEA-S), prolactin, growth hormone (hGH), adiponectin, and
leptin. In addition, we also quantified the expression levels of
transcripts, related to the GC activity (α and β isoforms of the GC
receptor -GR-), and the 11 beta hydroxysteroid dehydrogenase
type 1 (11βHSD1) and type 2 (11βHSD2) enzymes. Experiments
were also carried out to analyze whether high doses of cortisol
(mirroring a stressful situation) along with physiological and
supraphysiological glucose concentrations, or not, modified the
Mtb-induced response of peripheral blood mononuclear cells
(PBMC) from patients with TB+DMwhen compared to the ones
yielded by TB cases, patients with DM and sex and age matched
controls (Co). Assessments included lymphoproliferation studies
and production of pro and anti-inflammatory cytokines as well
as the Th1/Th2/Th17 profiles.
MATERIALS AND METHODS
Sample Population
Patients (14 females and 18 males) with no HIV co-infection
and newly diagnosed PTB were included. Diagnosis was
based on clinical and radiological examinations together with
the identification of Mtb bacilli in sputum. Eleven of these
patients were diagnosed as also having DM (TB+DM) and
21 with only PTB (TB). For DM diagnosis, the criteria of
the American Diabetes Association of 2009 were considered.
Those were hyperglycemia (based on two fasting glucose
levels >125 mg/dL or a random glucose level equal to or
higher than 200 mg/dL) evaluated on EDTA-anticoagulated
blood specimens.
The control groups were composed of 22 pair matched Co
and 18 individuals with DM, sharing the same socioeconomic
conditions of TB patients, unexposed to TB patients, with no
clinical or radiological evidence of PTB. Patients and Co had no
other respiratory disease, nor immune-compromising diseases.
The control group (Co) was composed of 22 individuals.
Another group of 18 patients with DM was also included for
comparison purposes. All of them were sex- and age-matched
and shared the same socioeconomic conditions of TB patients,
in addition to being unexposed to TB patients, with no clinical
or radiological evidence of PTB. All volunteers had no other
respiratory disease, nor immune-compromising diseases.
Participants were sampled by applying a consecutive non-
probabilistic approach. As such, the Co group had a median BMI
which fell within the range of overweight, as defined by WHO.
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Blood samples were obtained on study admission, in the
case of TB patients immediately before the initiation of anti-
tuberculosis treatment. Samples were collected at 8 a.m. to
avoid differences due to circadian variations. Exclusion criteria
included disease states affecting the adrenal glands or the
Hypothalamus—Pituitary- Adrenal (HPA) axis, corticosteroid
treatment, pregnancy, and age below 18 years. The body mass
index (BMI) was also calculated (weight/square of height). The
Bioethical Committee of the School ofMedical Sciences, National
University of Rosario, approved the protocol. All participants
gave their consent to participate in the study.
PBMC Isolation and Lymphoproliferation
Plasma and PBMC were obtained from fresh EDTA-treated
blood. Samples were centrifuged at 2000 rpm during 30min
and plasma was collected and stored at −20◦C. The buffy coat
was separated and diluted 1:1 in RPMI 1640 (PAA Laboratories
GmbH, Austria), containing standard concentrations of L-
glutamine, penicillin, and streptomycin (culture medium, CM).
The cell suspension was layered over a Ficoll-Paque Plus
gradient (density 1.077, Amersham Biosciences, NJ, USA), and
centrifuged at 400 g for 30min at room temperature (19–22◦C).
PBMC recovered from the interface were washed three times with
CM and resuspended in CM containing 10% heat-inactivated
pooled normal AB human sera (PAA Laboratories GmbH,
Germany). Cells were cultured in quadruplicate in flat-bottomed
microtiter plates (2 × 105 cells/well in 200 µl) with or without
addition of γ-irradiated H37Rv M. tuberculosis strain (Mtbi;
8µg/ml, Colorado University, USA). Concanavalin A (ConA;
2.5µg/ml, Sigma-Aldrich) was used as a proliferation positive
control. PBMC cultures were incubated for 5 days at 37◦C, in a
5%, CO2 humidified atmosphere and pulsed with
3H-thymidine
for 18 h before cell harvesting. The average counts per minute
(cpm) of stimulated and non-stimulated cultures were calculated.
Quantification of Cytokines and Hormones
in Plasma
Plasma levels of cytokines: IFN-γ (BD Pharmingen, detection
limit-DL: 4.7 pg/ml), IL-10 (BD Pharmingen, DL:3.9 pg/ml), IL-6
(DRG Diagnostics, DL: 2 pg/ml), IL-4 (BD Pharmingen, DL: 7.8
pg/ml), IL-1β (BD Pharmingen, DL: 3.9 pg/ml), and hormones
like Cortisol (DRG Diagnostics, DL: 2.5 ng/ml), DHEA-S (DRG
Diagnostics, DL: 0.108 ng/ml), prolactin (DRG Diagnostics,
DL: 0.35 ng/ml), hGH (DRG Diagnostics, DL: 0.17µIU/ml),
adiponectin (Invitrogen, DL: 100 pg/ml), and leptin (Invitrogen,
DL: 3.5 pg/ml) were assessed by commercial enzyme immune
analysis according to the manufacturer instructions. C reactive
protein (CRP) levels were measured by high-sensitivity Turbitest
(Wiener Lab, DL: 2.5 mg/l). All samples were processed
individually and assayed in duplicate.
Studies on the In vitro Effects of Cortisol
and Glucose
PBMC were cultured as above described (section PBMC
Isolation and Lymphoproliferation) with the addition of various
concentrations of cortisol (0.1µM y 1µM) (19) and/or D-
Glucose (Glc; physiological dose−5 mM- and supraphysiological
doses−10, 20, 40 mM- Sigma Aldrich) and further stimulated
with Mtbi, or not. PBMC were seeded in 96-well flat-bottomed
microtiter plates for the lymphoproliferation assay as previously
described (section PBMC Isolation and Lymphoproliferation).
The same protocol was performed in 24-well flat-bottomed
microtiter plates (1 × 106 cells/well). Supernatants were
obtained, fractionated and preserved at −20◦C until the
assessment of different cytokine patterns by means of the
Cytometric Bead Array Kit (LTCD4+ cells, CBA).
RNA Isolation, cDNA Synthesis and qPCR
Total RNA was isolated from PBMC using TRIreagent
(Genbiotech). RNA pellets were dissolved in Diethyl
pyrocarbonate (DEPC) sterile water and stored at −80◦C.
RNA quantity and integrity was assessed as reported earlier (20).
cDNA was synthesized from 2 µg of total RNA by extension of
oligodT primers with M-MuLV reverse transcriptase (Thermo)
in a final volume of 40 µl DEPC sterile water. cDNA was stored
at −80◦C until use. qPCR was performed with the StepOnePlus
(96-well) Real-Time PCR Systems (Applied Biosystems) using
3 µl of cDNA dilution, 0.4µM of each primer and 3 µl of
5x HOT FIREPol R© EvaGreen qPCR Mix Plus (ROX) (Solis
BioDyne), final volume of 15 µl. Thermal cycling conditions
were as follows: 10min at 95◦C followed by 45 PCR cycles of
denaturing at 95◦C for 20 s, 30 s for annealing at 60◦C and 30 s
for elongation at 72◦C. Fluorescence readings were performed
during 10 s at 80◦C before each elongation step. To normalize
the expression of every gene, the transcript of peptidylprolyl
isomerase A was used as an endogenous control on each
mononuclear cell sample (21). Serially diluted cDNA samples
synthesized from Jurkat and NCI-H295R cell line expressing
GRα, GRβ and 11βHSD1 and 11βHSD2 mRNA, respectively
(22, 23), were used as relative external standards curve in
each run, to make “The Relative Standard Curve Method” for
the relative quantification of gene expression, as performed
formerly (20). Similarity and homogeneity of PCR products
from samples were confirmed by automated melting curve
analysis (StepOne Software, Applied Biosystems), revealing
melting temperature values of the PCR products. Primers were
designed as described by D’Attilio et al. (24), Table 1. Data were
expressed as fold change of the relative expression levels of the
gene of interest (GOI) normalized by the relative expression
levels of PPIA.
Cytometric Bead Array
Cytokine quantification was done using the Human
Th1/Th2/Th17 CBA kit (BD Biosciences) which allowed
the simultaneous detection of IL-2, IL-4, IL-6, IL-10, TNF-α,
IFN-γ, and IL-17A (DL: 2.6; 4.9; 2.4; 4.5; 3.8; 3.7 and 18.9 pg/ml,
respectively). CBA analysis was performed according to the
manufacturer’s instructions. Cytokine supernatant levels were
calculated using BD CBA software (version 4.0, BD Biosciences).
Statistical Analysis
Comparisons between groups were made by non-parametric
methods: Kruskall–Wallis followed by post-hoc comparisons
when applicable. Qualitative variables were compared by the
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chi square test. Related samples were analyzed by means of
Wilcoxon and Friedman tests. Associations between variables
were analyzed using the Spearman correlation test. A value of p
< 0.05 was considered as statistically significant.
RESULTS
General Features of Study Groups
Table 2 shows the general characteristics from the different
study groups and diabetes-related biochemical findings. A lower
percentage of BCG vaccination was seen in the DM and TB+DM
groups with respect to Co, with the TB+DM group showing
TABLE 1 | Sequence of qPCR primers.




5′-gca tac ggg tcc tgg
catc ttg-3′
CycA-R








5′gaa gga aac tcc agc
cag aac-3′
GRα-R







5′-gaa gga aac tcc agc
cag aac-3′
GRβ –R







5′- atg ata ttc acc atg
tgc gca−3′
11βHSD1 R







5′-tcg cgc ggt gct cat
cac-3′
11βHSD2 R
5′- gta cgc agc tcg atg
gca cc-3′
132pb
PPIA, peptidylprolyl isomerase A; NR3C1, nuclear receptor subfamily 3 group C member
1; GR, glucocorticoids receptors; HSD11B1, hydroxysteroid 11-beta dehydrogenase 1;
HSD11B2, hydroxysteroid 11-beta dehydrogenase 2.
the lowest percentage of a BCG scar. The TB group showed a
significant decrease in the BMI if compared to Co and TB+DM.
Patients with DM showed the highest BMI, but their values
did not differ from the ones recorded in Co counterparts.
Mainly because, by chance, 23% of Co volunteers presented
a BMI within the normal weight range, whereas 55% and a
22% of them had values that fell in the overweight and obesity
categories, respectively. Regarding diabetes-related biochemical
findings (Table 2), DM and TB+DM groups had elevated blood
glucose levels (much higher in the latter group). The percentage
of glycosylated hemoglobin (HbA1c) was higher in both groups
of DM patients more pronounced in those with the TB+DM
comorbidity. Basal insulinemia was found increased only in
the TB+DM group, statistically different from the remaining
groups. When calculating the HOMA index (≥3.2 compatible
with insulin resistance), 67% of DM patients and 73% of
TB+DM fell in this category. It is worth reminding that most
DM were under treatment with metformin and fenofibrate.
In addition, the erythrocyte sedimentation rate (ESR) was
increased in both groups of patients with TB in relation to
their respective controls, while the DM group differed from the
Co-individuals (Table 2).
Plasma Quantification of Immunologic
Mediators and Hormones
Plasma Levels of Pro and Anti-inflammatory
Cytokines, Adiponectin, Leptin, Prolactin and hGH
Both groups of TB patients showed elevated values of IL-6,
CRP, and IFN-γ (Figures 1A–C), with TB+DM patients showing
even higher amounts of IFN-γ if compared to TB counterparts.
Patients with DM also displayed increased CRP levels. As regards
IL-10, this cytokine was increased in both groups of DM patients
(Figure 1D), as well as in the group of TB patients with severe










Age (years) 45 (35–62) 54 (51–61) 41 (34–59) 50 (41–62) n.s.
Sex (F/M) 9/13 10/8 8/13 6/5 n.s.
BCG (%) 95.4 78.9 76.2 45.5*#& 0.001
























































Co, controls; DM, patients with type 2 diabetes mellitus; TB, patients with pulmonary tuberculosis; TB+DM, patients with pulmonary tuberculosis and type 2 diabetes mellitus; n.s., not
significant; F, female; M, male; BCG, Bacillus Calmette-Guerin vaccination; BMI, body mass index. rv, reference values; HOMAIR index, [insulin (µIU/ml)
*glycemia (mmol/L)]/22.5; ESR,
Erythrocyte Sedimentation Rate. Results are shown as median (25-75 percentiles). *different from HCo, p < 0.05; #different from DM, p < 0.05; &different from TB, p < 0.05.
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FIGURE 1 | Plasma levels of IL-6 (A), IFN-γ (B), C reactive protein (CRP; C) and IL-10 (D) in controls (Co), patients with type 2 diabetes (DM), with pulmonary
tuberculosis (TB) or with TB and DM (TB-DM). Box plots show median values, 25–75 percentiles from data in each group with maximum and minimum values.
disease (data not shown). Assays for IL-4 and IL-1β yielded values
below the detection limits.
While adiponectin and prolactin concentrations showed no
differences among study groups (Figures 2A,C, respectively),
leptin levels appeared decreased in both TB patient groups,
much lower in those without DM (Figure 2B). hGH levels were
increased in both TB groups particularly in TB+DM cases
(Figure 2D).
An additional analysis by sex revealed that decreased levels of
leptin prevailed between both groups of men with TB even more
in those cases without DM. Regarding hGH, men with TB+DM
were the ones showing significantly increased amounts of this
hormone (data not shown).
Plasma Levels of Cortisol, DHEA and DHEA-S
As reported earlier, patients with TB had a higher cortisol
concentration (∗p < 0.04 vs. Co, Figure 3A), as did patients
with TB+DM (p < 0.04 vs. Co and p < 0.02 vs. DM). Plasma
concentrations of DHEA were significantly lower in TB group
compared to Co, but not in patients with TB+DM, who even
showed values higher than TB cases (Figure 3B). However,
DHEA-S levels were diminished in both groups of TB patients,
particularly the TB+DM ones, as well as DM cases (Figure 3C).
When analyzing the Cort/DHEA ratio (Figure 3D), this was
significantly increased in the three groups of patients compared
with those from Co, a bit less pronounced in the TB+DM group.
The same was true when comparing the Cort/DHEA-S ratio
(Figure 3E), with TB+DM differing in turn from DM.
Relative Levels of mRNAs Expression for
GRα, GRβ and the Enzymes 11βHSD1 and
11βHSD2 in PBMC From the Study Groups
As depicted in Figures 4A,B there were no significant differences
in transcript expression levels for GRα and GRβ, although the
GRα/GRβ ratio was found to be diminished in patients with TB
when compared with Co (Figure 4C). Regarding the 11βHSD1
mRNA, its levels were increased in both groups of patients with
DM, respect to those of Co, as well as TB+DM patients if
compared to TB (Figure 4D). In general terms the 11βHSD2
enzyme was not expressed, or at very low levels, even with
optimized reaction conditions (24).
Lymphoproliferation Studies
The effects of different Glc doses on the proliferative capacity
of PBMC against Mtbi are shown in Figure 6. Regardless
of the Glc dose, the blastogenic response of cells, expressed
as Stimulation Index (SI), from each study group showed a
similar pattern (Figure 5). For instance, the SI of the TB group
was lower than that from Co, and negatively correlated with
IL-10 levels (r = −0.54, p < 0.03), while both groups of
DM patients showed the highest responses, in the case of
TB+DM statistically significant from TB and Co groups. In
essence, increasing Glc concentrations did not modify the Mtbi-
driven blastogenesis in the four study groups (Figure 5). Data
from studies by adding cortisol in presence of different Glc
concentrations are summarized in Figure 6. The higher dose of
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FIGURE 2 | Plasma levels of adiponectin (A), leptin (B), prolactin (C) and human growth hormone (hGH, D) in controls (Co), patients with type 2 diabetes (DM), with
pulmonary tuberculosis (TB) or with TB and DM (TB-DM). Box plots show median values, 25–75 percentiles from data in each group with maximum and minimum
values.
cortisol (1µM) decreased proliferation regardless of the study
group or Glc concentration, being significantly lower than the
results obtained when using a lower cortisol dose (0.1µM;
Figures 6A–D). Between group differences in the blastogenic
response continued to show the pattern described in Figure 6,
regardless of the Glc or cortisol doses (Figures 6A–D). Notably,
hyperglycemia did not modify the inhibitory cortisol effect
(Figures 7A,B).
Quantification of Mediators in Culture
Supernatants of PBMC
According to the study purposes, 24 h culture supernatants from
PBMC subjected to the above described treatments (Materials
and Methods section Studies on the In vitro Effects of Cortisol
and Glucose), were assessed for the levels of proinflammatory
(TNF-α, IL-1β, IL-6), and anti-inflammatory (IL-10) cytokines
as well as the ones representing the Th1 (IL-2, IFN-γ), Th2
(IL-4) and Th17 (IL-17A) profiles. According to data from the
lymphoproliferation studies, we decided to quantify cytokines in
six parallel cultures undergoing one of the following stimulation
procedures: Glc 5mM, Glc 20Mm, Glc 5 mM+ Mtbi, Glc 20
Mm+ Mtbi, Glc 5mM + Cortisol 1µM + Mtbi, Glc 20mM +
Cortisol 1µM + Mtbi. All Mtbi-stimulated cultures contained
increased levels of TNF-α, IL-1β, IL-2, IFN-γ, and IL-10 which
remained unmodified by Glc treatment even at the 20µM dose,
except for IL-1β production from PBMC of Co (Table 3). IL-
6 levels were largely increased before stimulation, beyond the
upper detection limits of the Kit, whereas IL-4 and IL-17A
remained undetectable.
When comparing cytokine production, cultured PBMC of
patients with TB+DM had the highest levels of IL-2 (Figure 8)
and IFN-γ (Figure 9), in the case of IL-2 statistically different
from the remaining groups (Figures 8A,B). Levels of TNF-α,
IL-1β, and IL-10, in stimulated cultures were similar for all
study groups (data not shown). Cortisol treatment decreased
the production of all above described cytokines, regardless of
subject groups or Glc doses (Figures 8, 9). As regards to IL-
2 (Figures 8A,B), although their levels dropped, they remained
significantly elevated in the TB+DM group respect to the
remaining groups. The same was true when analyzing IFN-
γ concentrations, although differences were only significant in
relation to Co and DM (Figures 9A,B).
DISCUSSION
TB-DM comorbidity became more relevant in recent decades
due to the diabetic population marked increase; particularly
in low and middle-income countries, where PTB is prevalent.
Both pathologies present, by themselves, alterations in the
bidirectional communication between the immune and
neuroendocrine systems, with an important impact on the
metabolic component (25–27).
Our work evidenced that both groups of PTB patients
presented an important inflammatory response, reflected in
high systemic levels of IL-6, CRP, and IFN-γ. Several reports
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FIGURE 3 | Plasma levels of cortisol (A), dehydroepiandrosterone (DHEA, B), dehydroepiandrosterone-sulfate (DHEA-S, C), cortisol/DHEA ratio (D) and
cortisol/DHEA-S ratio (E) in controls (Co), patients with type 2 diabetes (DM), with pulmonary tuberculosis (TB) or with TB and DM (TB-DM). Box plots show median
values, 25–75 percentiles from data in each group with maximum and minimum values.
indicate a greater increase of proinflammatory mediators in
PTB patients suffering DM compared to non-diabetic patients
(28, 29). This may reinforced by the increased presence of hGH
in plasma from TB+DM cases, considering that this hormone
exerts a contributory role for the development of the IR and the
accompanying inflammation (30, 31).
As in previous studies (32–34), patients with only TB showed
decreased blastogenesis, which in turn correlated negatively
with IL-10 levels, a cytokine of recognized inhibitory effect on
lymphoproliferation (35). Such decreased specific proliferation
may be partly attributed to a recruitment of cells committed
toward the site of the lesion (19). This mechanism seems to be
altered in diabetic patients with active PTB (27, 36) and could to
account for the increasedMtb-driven mitogenesis of PBMC.
The systemic increase of IL-10 from TB+DM patients,
also reported by Kumar and collaborators (37), may be
mirroring a regulatory mechanism of IR, given its well-
known anti-inflammatory and anti-proliferative effects (35,
38). At the same time, IL-10 seems to be detrimental in
mouse and human TB, as it favors mycobacterial survival in
macrophages by inhibiting phagosome maturation, reducing
NO production (39) and in turn blocking IFN-γ (40, 41)
signaling. Some studies suggest that IL-10 would be a marker
of disease progression (42–46). In our cases, analysis according
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FIGURE 4 | Relative expression of mRNA glucocorticoids receptor (GR) isoforms α (GR α, A) and β (GRβ, B), 11βHSD1 enzyme (D), and the GRα/GRβ ratio (C) in
peripheral blood mononuclear cells (PBMC) from controls (Co), patients with type 2 diabetes (DM), with pulmonary tuberculosis (TB) or with TB and DM (TB-DM). Data
are expressed as fold change respect to PPIA. Box plots show median values, 25–75 percentiles from data in each group with maximum and minimum values.
FIGURE 5 | Effects of supraphysiological glucose doses on Mtbi-induced proliferation of peripheral blood mononuclear cells (PBMC) from controls (Co), patients with
type 2 diabetes (DM), with pulmonary tuberculosis (TB) or with TB and DM (TB-DM). Mtbi: γ-irradiated H37Rv M. tuberculosis strain. Results are shown as Stimulation
index (SI: average of counts per minute -cpm- in Mtbi stimulated cultures/average of cpm in unstimulated cultures). Box plots show median values, 25–75 percentiles
from data in each group with maximum and minimum values. +different from HCo, p < 0.02; &different from TB, p < 0.003; #different from DM, p < 0.05; in each
case when comparing with the same glucose dose.
to disease severity showed a significant increase of IL-10 in
TB+DM patients with progressive pulmonary involvement (data
not shown).
Notably, IL-10 levels were also augmented in DM patients
who also displayed increased amounts of CRP together
with a high ESR resembling some sort of pro- and anti-
inflammatory influences.
As seen in former studies (33, 34, 47, 48), the unbalanced
relationship between steroid hormones recorded in TB patients,
increased and decreased levels of cortisol and DHEA-DHEA-
S, respectively, was also found in TB+DM patients. This may
be explained by assuming that the adrenal gland is trying to
preserve cortisol production at the expense of DHEA synthesis,
to counteract the inflammatory response accompanying active
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FIGURE 6 | Effects of glucose doses (5mM, A; 10mM, B; 20mM, C; 40mM, D) on cortisol-induced inhibition of Mtbi-blastogenesis by peripheral blood mononuclear
cells (PBMC) from controls (Co), patients with type 2 diabetes (DM), with pulmonary tuberculosis (TB) or with TB and DM (TB-DM). Mtbi: γ-irradiated H37Rv M.
tuberculosis strain. Results are shown as Stimulation index (SI: average of counts per minute -cpm- in Mtbi stimulated cultures/average of cpm in unstimulated
cultures). Box plots show median values, 25–75 percentiles from data in each group with maximum and minimum values. +different from Co, p < 0.04; &different
from TB, p < 0.02; #different from DM, in each case when comparing the same treatment between groups, p < 0.05; *different from cultures without cortisol and
from those treated with 0.1 uM cortisol within the same group, p < 0.05.
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FIGURE 7 | Effects of glucose doses on Mtbi-blastogenesis of peripheral blood mononuclear cells (PBMC) from in controls (Co), patients with type 2 diabetes (DM),
with pulmonary tuberculosis (TB) or with TB and DM (TB-DM) treated with cortisol 0.1µM (A) or 1µM (B). Mtbi: γ-irradiated H37Rv M. tuberculosis strain. Results are
shown as Stimulation index (SI: average of counts per minute -cpm- in Mtbi stimulated cultures/average of cpm in unstimulated cultures). Box plots show median
values, 25–75 percentiles from data in each group with maximum and minimum values. +different from Co, p < 0.04; &different from TB, p < 0.02; #different from
DM, p < 0.05; in each case when comparing with the same glucose dose.
disease. Decreased levels of DHEA and DHEA-S, may be
detrimental in TB, since they preferentially favor the Th1 profile
of the IR in addition to exerting anti-inflammatory activities (49–
52). DHEA-S is not bioactive; but constitutes the natural reservoir
of DHEA being therefore a stable marker of its availability.
As regards GR isoforms, while high GC-responsiveness would
typically reduce GRα increasing GRβ and therefore dampening
GC effects, this was not so evident in TB, probably because of
its chronic nature and several endocrine alterations. The reduced
GRα/GRβ ratio seen in TB patients is compatible with a certain
degree of resistance to GC endogenous function. In a recent
study, Martins et al. reported that GRβ expression levels were
dramatically increased in PBMC of patients with the metabolic
syndrome compared to lean controls (53). Our present lack of
GRβ transcript alterations in control subjects may be explained
by considering that their BMI situated below the ones displayed
by the group of dysmetabolic Brazilian patients. Mouse studies
revealed that GRβ causes higher glucose levels along with and
increased immune-inflammatory response (54), but in our hands
GRβ expression was not associated to any particular change in
the profile of metabolic or immune-endocrinemediators. Despite
TB+DM cases showed no differences in the GRα/GRβ ratio,
transcriptional levels of 11βHSD1, which favors the availability of
cortisol at the cellular level, were clearly elevated in both groups
of DM patients. The fact that TB+DM patients presented high
levels of plasma cortisol, along with 11βHSD1 transcripts and
IFN-γ values points out to some degree of HPA axis dysfunction
and/or GC resistance in them (55, 56).
The lower BMI from TB patients is in line with our former
demonstrations in this regard, in which we also documented
a negative association between BMI and IL-6 levels, probably
reflecting the high-energy demand required to support the
chronic inflammatory response (48, 57). In the case of TB+DM
patients they exhibit a negative association between cortisol levels
and BMI (data not shown). With regard to TB+DM patients,
60% of them fell within the overweight category in line with
some evidence indicating an association between overweight and
obesity with an increased risk for DM and pre-DM development
(58–60). While 77% of individuals from the Co group had a
high BMI, our findings are in line with a report from WHO
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(GLOBAL STATUS REPORT on non-communicable diseases
2014), referring to an increase in BMI in most developing
countries between the 2010–2014 period, in our country from
27.2 to 27.8 (61).
Present results in TB patients are consistent with our earlier
studies (48), revealing an orexigenic pattern characterized by
low and high levels of leptin and adiponectin, respectively. This
not being the case of TB+DM patients in whom leptin levels
appeared diminished to a lesser extent, with no changes in
adiponectin concentrations. Reduced levels of leptin in both
groups of patients with TB may be partly due to the high
systemic amounts of proinflammatory mediators, known to
suppress leptin synthesis (62, 63). The different pattern seen
in TB+DM patients may have to do with their preserved or
even increased BMI, implying a greater adiposity. Likewise,
leptin has been reported as facilitating the cellular response,
particularly that of the Th1 profile (64). Adiponectin was
found reduced in dysregulated diabetic patients, compared to
slim controls (65), but in our study we found differences in
this regard. Between study differences may be explained by
considering that most DM patients were being treated for their
diabetes, and their BMI was comparable to the one recorded
in Co group.
The inflammatory component observed in DM and TB+DM
patients is likely to account for their insulin resistance, mainly in
the former group (66–68). Decreased amounts of both androgens
(DHEA and DHEA-S) may be also implied in insulin resistance,
since they favor body weight (69, 70) and adipose tissue reduction
(71) while stimulating Glc uptake (70, 72).
Moving to the immune-metabolic communication, innate and
adaptive immune cells must respond rapidly in the presence
of noxious stimuli, for which they must drastically alter their
metabolism to achieve a high rate of cell division, as well as
the synthesis and secretion of various molecules necessary for
the development of a protective IR. While leukocytes use several
types of energy sources (fatty acids, cholesterol, vitamins, trace
elements, amino acids, monosaccharides), Glc and glutamine
emerge as the main metabolic substrates, representing 70% of
energy sources (73).
Studies assessing the immune status of DM patients
against several microbial antigens showed a dysfunctionality
of innate and adaptive cells, particularly in cases with chronic
hyperglycemia (high HbA1c levels) (14, 74). Such alterations
appeared to reverse under a proper glycemic control (14,
75–77), although transient and chronic hyperglycemia induce
epigenetic modifications, known under the term “metabolic
memory” likely to influence substantially immunocompetent cell
activity (78, 79).
In the present study, Mtbi-stimulated PBMCs from TB+DM
patients showed the highest mitogenic response together with an
abundant production of IL-2 and IFN-γ. Present results are in
line with the study by Restrepo et al. showing a predominant
Th1 profile upon PPD stimulation of PBMC from patients with
this comorbidity (28). Kumar et al. reported the presence of a
Th1/Th17 profile when studying cells from TB+DM cases (80),
while Stalenhoef et al. found no differences in IFN-γ production
levels when comparing TB patients with or without DM (81).
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FIGURE 8 | IL-2 production by cultures of peripheral blood mononuclear cells (PBMC) from in controls (Co), patients with type 2 diabetes (DM), with pulmonary
tuberculosis (TB) or with TB and DM (TB-DM), stimulated with Mtbi and treated with glucose 5mM (A) and 20mM (B) with or without cortisol (1µM). Mtbi:
γ-irradiated H37Rv M. tuberculosis strain. Box plots show median values, 25–75 percentiles from data in each group with maximum and minimum values. +different
from Co, p < 0.03; &different from TB, p < 0.04; #different from DM, p < 0.04; in each case when performing between-group comparisons for the same treatment;
*different from cultures without cortisol within the same group. p < 0.03.
Such dissimilarities may be due to ethnical differences, control
status of DM and experimental conditions, among others.
In line with the well-known immunostimulant effects of IL-2
(82), in our case IL-2 levels were positively associated with Mtb-
driven proliferation in DM and Co individuals, as well as with
IFN-γ in all study groups. The increased in vitro synthesis of IFN-
γ by stimulated PBMC from TB+DM patients was paralleled by
augmented amounts of this cytokine in circulation. While being
critical for mycobacterial elimination (83, 84), IFN-γ also exerts
proinflammatory effects likely to mediate tissue damage when
improperly regulated. As such, and over-expansion of cells with
a Th1 profile may constitute a double-edged sword in the context
of TB+DM.
Hyperglycemia can lead to an inflammatory state through
several pathways (85–87) with advanced glycation end products
playing a substantial role is this regard. These products,
which are abundant in uncontrolled diabetic patients, promote
inflammation not only by activating NF-kB (88) but also by
working in combination with other inflammatory mediators
like the high mobility group box 1 protein to aggravate the
inflammatory process (89, 90). Consequently, DM individuals
with uncontrolled hyperglycemia are likely to show a greater
inflammatory and lymphoproliferative response upon exposure
to an infectious agent, increasing tissue damage as well. In
our hands, both groups of DM patients had the greatest SI,
statistically significant in TB+DM, who in turn showed an
increased IL-2 and IFN-γ production.
In vitro studies have shown an increased release of
inflammatory cytokines by PBMC from healthy individuals when
exposed to supraphysiological doses of Glc (91, 92). Lachmandas
et al. observed that PBMC from healthy people produced
higher levels of TNF-α, IL-1β, and IL-6 before stimulation in a
hyperglycemic microenvironment, without changes in the levels
of IFN-γ, IL-17A, and IL-22, suggesting that Glc would have a
greater effect on monocytes than in lymphocytes (18, 83, 84).
In our case, specific stimulation under a hyperglycemic
scenario led to an increased IL-1β production only in Co
cells, with the specific lymphoproliferation and production of
other mediators being unmodified no matter the study groups.
Differences in technical approaches, i.e., stimulation procedures
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FIGURE 9 | IFN-γ production by cultures of peripheral blood mononuclear cells (PBMC) from controls (Co), patients with type 2 diabetes (DM), with pulmonary
tuberculosis (TB) or with TB and DM (TB-DM), stimulated with Mtbi and treated with glucose 5mM (A) and 20mM (B) with or without cortisol (1µM). Mtbi:
γ-irradiated H37Rv M. tuberculosis strain. Box plots show median values, 25–75 percentiles from data in each group with maximum and minimum values. +different
from Co, p < 0.04; #different from DM, p < 0.05; in each case when performing between-group comparisons for the same treatment; *different from cultures without
cortisol within the same group p < 0.03.
and time point evaluations, may account for inconsistencies
between present studies and former reports.
Our former demonstration that cortisol treatment, at doses
resembling an acute stress situation, inhibited the specific
proliferative response and synthesis of IFN-γ by PBMC of TB
patients and Co (19) along with the increased systemic levels
of cortisol of TB+DM patients, prompted us to analyze cortisol
effects in them. As seen in TB patients, high cortisol doses
inhibited proliferative capacity and production of TNF-α, IL-
1β, IL-2, IFN-γ, and IL-10, in TB+DM and DM patients as
well as Co. Although TB+DM continued to show a remarkable
response despite this steroid treatment. Cortisol inhibitory
effects on pro-inflammatory cytokine production are achieved
by several transcriptional repression mechanisms (93–97), with
some inconsistencies as to its role in the production of
anti-inflammatory mediators in light of evidence reporting a
stimulating or inhibitory influences on IL-10 in vitro synthesis
(98–102). Whether the present diminished IL-10 production
is to some extent related to the decreased TNF-α and IFN-γ
synthesis, which by themselves may promote IL-10 production
(103), remains to be established.
Although the effects of Glc and cortisol on IR have been
extensively analyzed, their combined effect on PBMC had not
been studied so far. As shown, high Glc doses did not modify
the cortisol-induced inhibition on mitogenesis, nor cytokine
production from different study groups.
The bulk of presented results points out that the
deregulated immune-endocrine-metabolic status from
DM patients becomes more pronounced in those with
the TB comorbidity. This is supported not only by the
further increased systemic proinflammatory response
of TB+DM patients but also for the demonstration
that PBMC are more likely to develop an exacerbated
response against Mtb, reflected in a more pronounced
Th1 profile. A better control of the diabetic status will
promote a more favorable course of TB in the context of
TB+DM comorbidity.
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